Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG22515 in Moderate-to-severe Thyroid Eye Disease
NCT06557850Phase 1Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of Lu AG22515 in thyroid eye disease (TED), sponsored by Lundbeck. Primary endpoint: Change in Proptosis from Baseline at Week 24. Started Sep 2024; status: active, not recruiting.
02
Drugs
Lu AG22515
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06557850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557850.